AEON Biopharma, Inc. Class A (AEON) earnings
AEON earnings moved a median of -4.78% by the close. Quarterly and annual AEON reports and results, each read against the price at its own news timestamp. Back to the AEON overview →
17 measured AEON earnings events.
Where these AEON earnings landedvs 17 measured AEON earnings reactions
| Middle 50% of AEON earnings reactions | -4.81% to -3.07% |
|---|---|
| Median reaction (to close) | -4.78% |
| Measured reactions | 17 |
Point-in-time · zero look-ahead
Half of the 17 AEON earnings events with a measured close landed between -4.81% and -3.07%; 18% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | -1.28% | -3.80% | |
| AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | +0.00% | -7.49% | |
| AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth | Press release | -5.18% | -4.78% | |
| Form 10-Q AEON Biopharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | -5.18% | -4.78% | |
| Form 10-Q AEON Biopharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | -1.33% | +19.67% | |
| Form 10-K/A AEON Biopharma, Inc. For: Dec 31 | SEC filing · Form 10-K | -5.15% | -3.84% | |
| Form 10-Q/A AEON Biopharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | -5.15% | -3.84% | |
| AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update | Press release | +3.10% | +6.02% | |
| Form 10-Q AEON Biopharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | +3.10% | +6.02% | |
| Form 10-K AEON Biopharma, Inc. For: Dec 31 | SEC filing · Form 10-K | -2.29% | -9.30% | |
| AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | +0.90% | -12.60% | |
| Form 10-Q AEON Biopharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.90% | -12.60% | |
| AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update | Press release | +0.00% | -4.81% | |
| Form 10-K/A AEON Biopharma, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | -4.81% | |
| Form 10-Q AEON Biopharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -4.81% | |
| AEON Biopharma Reports First Quarter 2024 Financial Results | Press release | +1.82% | -3.07% | |
| AEON Biopharma Reports Third Quarter 2023 Financial Results | Press release | — | -1.20% |
Keep exploring
More AEON: analyst actions → · SEC filings → · AEON overview →